Mostrar el registro sencillo del ítem

dc.contributor.authorBerrio, Indira
dc.contributor.authorCaceres, Diego H.
dc.contributor.authorCoronell R, Wilfrido
dc.contributor.authorSalcedo, Soraya
dc.contributor.authorMora, Laura
dc.contributor.authorMarin, Adriana
dc.contributor.authorVarón, Carmen
dc.contributor.authorLockhart, Shawn R.
dc.contributor.authorEscandón, Patricia
dc.contributor.authorBerkow, Elizabeth L.
dc.contributor.authorRivera, Sandra
dc.contributor.authorChiller, Tom
dc.contributor.authorVallabhaneni, Snigdha
dc.date.accessioned2020-05-21T17:33:48Z
dc.date.available2020-05-21T17:33:48Z
dc.date.issued2020
dc.identifier.issn20487207
dc.identifier.urihttps://hdl.handle.net/20.500.12442/5708
dc.description.abstractBackground. Candida auris is an emerging multidrug-resistant yeast that can cause invasive infections and healthcareassociated outbreaks. Here, we describe 34 cases of pediatric C. auris bloodstream infections (BSIs) identified during July 2014– October 2017 in 2 hospitals in Colombia. Methods. We conducted a retrospective review of microbiology records for possible C. auris cases in 2 hospitals in Barranquilla and Cartagena. BSIs that occurred in patients aged <18 years confirmed as C. auris were included in this analysis. Results. We identified 34 children with C. auris BSIs. Twenty-two (65%) patients were male, 21% were aged <28 days, 47% were aged 29–365 days, and 32% were aged >1 year. Underlying conditions included preterm birth (26%), being malnourished (59%), cancer (12%), solid-organ transplant (3%), and renal disease (3%). Eighty-two percent had a central venous catheter (CVC), 82% were on respiratory support, 56% received total parenteral nutrition (TPN), 15% had a surgical procedure, and 9% received hemodialysis. Preinfection inpatient stay was 22 days (interquartile range, 19–33 days), and in-hospital mortality was 41%. Conclusions. Candida auris affects children with a variety of medical conditions including prematurity and malignancy, as well as children with CVCs and those who receive TPN. Mortality was high, with nearly half of patients dying before discharge. However, unlike most other Candida species, C. auris can be transmitted in healthcare settings, as suggested by the close clustering of cases in time at each of the hospitals.eng
dc.format.mimetypepdfspa
dc.language.isoengeng
dc.publisherOxford University Presseng
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourceJournal of the Pediatric Infectious Diseases Societyeng
dc.subjectBloodstream infectionseng
dc.subjectCandida auriseng
dc.subjectChildreneng
dc.titleBloodstream infections with Candida auris among children in Colombia: Clinical characteristics and outcomes of 34 Caseseng
dc.typearticleeng
dcterms.referencesForsberg K, Woodworth K, Walters M, et al. Erratum: Candida auris: the recent emergence of a multidrug-resistant fungal pathogen. Med Mycol 2019; 57:e7.eng
dcterms.referencesBenedict K, Roy M, Kabbani S, et al. Neonatal and pediatric candidemia: results from population-based active laboratory surveillance in four US locations, 2009– 2015. J Pediatric Infect Dis Soc 2018; 7:e78–85.eng
dcterms.referencesTsay S, Welsh RM, Adams EH, et al.; MSD. Notes from the field: ongoing transmission of Candida auris in health care facilities—United States, June 2016–May 2017. MMWR Morb Mortal Wkly Rep 2017; 66:514–5.eng
dcterms.referencesEyre DW, Sheppard AE, Madder H, et al. A Candida auris outbreak and its control in an intensive care setting. N Engl J Med 2018; 379:1322–31.eng
dcterms.referencesRecommendations for identification of Candida auris. 2018. Available at: https://www.cdc.gov/fungal/candida-auris/recommendations.html. Accessed 16 October 2019.eng
dcterms.referencesEscandón P, Chow NA, Caceres DH, et al. Molecular epidemiology of Candida auris in Colombia reveals a highly related, countrywide colonization with regional patterns in amphotericin B resistance. Clin Infect Dis 2019; 68:15–21.eng
dcterms.referencesMorales-López SE, Parra-Giraldo CM, Ceballos-Garzón A, et al. Invasive infections with multidrug-resistant yeast Candida auris, Colombia. Emerg Infect Dis 2017; 23:162–4.eng
dcterms.referencesCalvo B, Melo AS, Perozo-Mena A, et al. First report of Candida auris in America: clinical and microbiological aspects of 18 episodes of candidemia. J Infect 2016; 73:369–74.eng
dcterms.referencesChowdhary A, Sharma C, Duggal S, et al. New clonal strain of Candida auris, Delhi, India. Emerg Infect Dis 2013; 19:1670–3.eng
dcterms.referencesLockhart SR, Jackson BR, Vallabhaneni S, et al. Thinking beyond the common Candida species: need for species-level identification of Candida due to the emergence of multidrug-resistant Candida auris. J Clin Microbiol 2017; 55:3324–7.eng
dc.rights.accessrightsinfo:eu-repo/semantics/restrictedAccessspa
oaire.versioninfo:eu-repo/semantics/publishedVersionspa
dc.type.driverarticleeng
dc.identifier.doihttps://doi.org/10.1093/jpids/piaa038


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

  • Artículos
    Artículos científicos evaluados por pares

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 Internacional